A Pilot Double-Blind Randomized Trial of Perampanel for Essential Tremor.

ABSTRACT:

Background

Perampanel is a noncompetitive antagonist of alpha-amino-3-hydroxy-5-methylisoxazole propionic acid glutamate receptors suggested to modulate tremor.

Objectives

To assess the efficacy and tolerability of perampanel for essential tremor.

Methods

This was a double-blind, placebo-controlled, randomized, cross-over trial involving 26 patients titrated to 8 mg/day or a lower maximally tolerated dose as monotherapy or adjunct to antitremor medication. Tremor was assessed at the beginning and end of each 14-week treatment arm. The primary endpoint was change in the videotaped performance subscale of The Essential Tremor Rating Assessment Scale, scored by a blinded rater. Secondary endpoints included change in The Essential Tremor Rating Assessment Scale Activity o

SUBMITTER: Handforth A 

PROVIDER: S-EPMC7197304 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature